ADCC: Antibody-dependent cellular cytotoxicity (ADCC) is one major mode of action of therapeutic monoclonal Abs (mAbs). The immune mechanism relies on mAb dual activity: the variable region ensures the specific recognition of an antigen expressed by a target cell, and the Fc in the constant region binds to Fc receptors (FcRs) at the surface of effector cells. Once the effector cells are activated, they will release cytotoxic granules and kill the target cells.

We provide two ADCC assay formats：

1.     Measurement of LDH-release in PBMC mediated target cell killing system

2.     Measurement of CD16 signal activation in Jurkat-NFAT-CD16 reporter coculture system

Assay Specifications:

Assays are performed using a 96-well format. Each data point is tested in triplicate, and appropriate assay controls are included. 

Case study:

Turn-Around Time

2 - 3 weeks

Timeline & pricing may vary depending on custom assay specifications.

ADCP: Similar to ADCC, another major Fc effector function is antibody-dependent cellular phagocytosis (ADCP). This immune mechanism relies on antibodies’ ability to recognizes target cells and activate the FcγRs on the surface of macrophages to induce phagocytosis, resulting in internalization and degradation of the target cell through phagosome acidification.

We provide two ADCP assay formats：

1.     Measurement of phagocytic index (number of cells ingested per 100 macrophages) in CFSE-labeled tumor cells coculture with peripheral blood-derived macrophages.

2.     Measurement of CD32 signal activation in Jurkat-NFAT-CD32 reporter coculture system

Assay Specifications:  

Assays are performed using a 96-well format. Each data point is tested in triplicate, and appropriate assay controls are included. 

Case study:

Turn-Around Time

2 - 3 weeks

Timeline & pricing may vary depending on custom assay specifications.

CDC: Complement-dependent cytotoxicity (CDC) is a potent effector mechanism of IgG and IgM antibodies. It is initiated when the protein C1q complex binds to the antibody-antigen complex and triggers the classical complement pathway. It is one important mechanism of action by which therapeutic antibodies and antibody fragments can achieve the antitumor effect.

Assay Specifications:  

Assays are performed using a 96-well format. Each data point is tested in triplicate, and appropriate assay controls are included. 

Case study:

Turn-Around Time

2 - 3 weeks

Timeline & pricing may vary depending on custom assay specifications.